Regulus, UC San Diego team on microRNA

Regulus Therapeutics is working with researchers from the University of California, San Diego School of Medicine to identify new microRNA therapeutics for the treatment of angiogenic diseases. Angiogenesis--the formation of new blood vessels--plays a major role in the severity of cancer, diabetes, macular degeneration, inflammatory disease and arthritis, according to the release. Researcher pairs Regulus' microRNA platform with the university's expertise in animal models of angiogenesis. The program has already received a UC Discovery Grant, which is awarded to promote universities/industry partnerships. Financial details of the deal were not disclosed.

"The objective of our collaborative work with Regulus is to advance these initial discoveries and discover additional microRNAs involved in angiogenic diseases," explained David A. Cheresh, Ph.D., professor of pathology in the UCSD School of Medicine.

- take a look at the Regulus release

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.